Skip to main content
Erschienen in:

23.03.2020 | Original Article

Relations between disease status and body composition in pediatric inflammatory bowel disease

verfasst von: Saurabh Talathi, Pooja Nagaraj, Traci Jester, Jeanine Maclin, Taylor Knight, Margaux J. Barnes

Erschienen in: European Journal of Pediatrics | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

To evaluate the effect of remission status on physical activity and body composition in pediatric patients with inflammatory bowel disease (PIBD) and healthy peers. Single-center cohort study, including 54 PIBD patients and 33 healthy peers. During the initial study visit, a brief demographic questionnaire, physical activity questionnaire completed by participants, and instructions on recording dietary intake were given. Physicians completed the Physician Global Assessment (PGA) for disease severity. Medical chart abstraction was done to obtain disease variables of interest. DEXA scan completed 1 week later to obtain information on body composition. Variables of interest were compared between the three groups (IBD-Remission, IBD-Active, and healthy controls) using an ANOVA or Chi-square test as appropriate. IBD patients were older than controls, reported lower quality of life (73.9 vs. 80.9), and engaged in less MVPA (195.4 versus 361.1). The IBD-Active group had a significantly lower lean body mass, bone mineral density, and time spent in MVPA compared to the IBD-Remission group and healthy controls. IBD-Remission group had a significantly lower percentage of biologic use (55% vs. 87%) and comorbidities (26% vs. 44%) compared to IBD-active group. IBD-remission group also had a lower fat mass percentage. In this study, we report significantly favorable LBM, BMD, and time spent in MVPA in patients with IBD in remission compared to those not in remission with the former demonstrating a body composition resembling that of healthy peers.
Conclusion: While an improvement in BMD was observed with remission, the scores were still lower than controls.
What is Known:
• Body composition deficits in pediatric inflammatory bowel disease are common and some persist despite achievement of remission leading to long term outcomes including osteopenia and osteoporosis.
• Weight restoration in patients with pediatric IBD is primarily explained by gains in fat mass without similar gains in lean mass.
What is New:
• While an improvement in bone mineral density was observed, the achievement of remission significantly improves affects physical activity and body composition in pediatric inflammatory bowel disease.
• However, some parameters of body composition do not reach levels comparable to healthy peers.
Literatur
1.
5.
Zurück zum Zitat Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Singh H, Otley AR, Vutcovici M, el-Matary W, Nguyen GC, Griffiths AM, Mack DR, Jacobson K, Mojaverian N, Tanyingoh D, Cui Y, Nugent ZJ, Coulombe J, Targownik LE, Jones JL, Leddin D, Murthy SK, Kaplan GG (2017) Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases. Am J Gastroenterol 112(7):1120–1134PubMedPubMedCentralCrossRef Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Singh H, Otley AR, Vutcovici M, el-Matary W, Nguyen GC, Griffiths AM, Mack DR, Jacobson K, Mojaverian N, Tanyingoh D, Cui Y, Nugent ZJ, Coulombe J, Targownik LE, Jones JL, Leddin D, Murthy SK, Kaplan GG (2017) Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases. Am J Gastroenterol 112(7):1120–1134PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan F, Weisdorf-Schindele S, San Pablo W Jr, Perrault J, Park R, Yaffe M, Brown C, Rivera-Bennett MT, Halabi I, Martinez A, Blank E, Werlin SL, Rudolph CD, Binion DG, Wisconsin Pediatric Inflammatory Bowel Disease Alliance (2003) Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 143(4):525–531PubMedCrossRef Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan F, Weisdorf-Schindele S, San Pablo W Jr, Perrault J, Park R, Yaffe M, Brown C, Rivera-Bennett MT, Halabi I, Martinez A, Blank E, Werlin SL, Rudolph CD, Binion DG, Wisconsin Pediatric Inflammatory Bowel Disease Alliance (2003) Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 143(4):525–531PubMedCrossRef
7.
Zurück zum Zitat Guariso G, Gasparetto M (2017) Treating children with inflammatory bowel disease: current and new perspectives. World J Gastroenterol 23(30):5469–5485PubMedPubMedCentralCrossRef Guariso G, Gasparetto M (2017) Treating children with inflammatory bowel disease: current and new perspectives. World J Gastroenterol 23(30):5469–5485PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Sandborn WJ (2008) Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 135(5):1442–1447PubMedCrossRef Sandborn WJ (2008) Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 135(5):1442–1447PubMedCrossRef
9.
Zurück zum Zitat Van der Meulen-de Jong A, Aantjes M, Verwey M, Peek-Kuijt N, Maljaars P (2017) P559 Treatment goals in IBD: a perspective from patients and their partners. J Crohn's Colitis 11(suppl_1):S365–S365 Van der Meulen-de Jong A, Aantjes M, Verwey M, Peek-Kuijt N, Maljaars P (2017) P559 Treatment goals in IBD: a perspective from patients and their partners. J Crohn's Colitis 11(suppl_1):S365–S365
10.
Zurück zum Zitat Hill RJ (2014) Update on nutritional status, body composition and growth in paediatric inflammatory bowel disease. World J Gastroenterol 20(12):3191–3197PubMedPubMedCentralCrossRef Hill RJ (2014) Update on nutritional status, body composition and growth in paediatric inflammatory bowel disease. World J Gastroenterol 20(12):3191–3197PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Aloi M, Tromba L, Di Nardo G et al (2012) Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. J Pediatr 161(4):589–594 e581PubMedCrossRef Aloi M, Tromba L, Di Nardo G et al (2012) Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. J Pediatr 161(4):589–594 e581PubMedCrossRef
12.
Zurück zum Zitat Markowitz J, Grancher K, Rosa J, Aiges H, Daum F (1993) Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 16(4):373–380PubMedCrossRef Markowitz J, Grancher K, Rosa J, Aiges H, Daum F (1993) Growth failure in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 16(4):373–380PubMedCrossRef
13.
Zurück zum Zitat Ishige T (2019) Growth failure in pediatric onset inflammatory bowel disease: mechanisms, epidemiology, and management. Transl Pediatr 8(1):16–22PubMedPubMedCentralCrossRef Ishige T (2019) Growth failure in pediatric onset inflammatory bowel disease: mechanisms, epidemiology, and management. Transl Pediatr 8(1):16–22PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Vasseur F, Gower-Rousseau C, Vernier-Massouille G, Dupas JL, Merle V, Merlin B, Lerebours E, Savoye G, Salomez JL, Cortot A, Colombel JF, Turck D (2010) Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 105(8):1893–1900PubMedCrossRef Vasseur F, Gower-Rousseau C, Vernier-Massouille G, Dupas JL, Merle V, Merlin B, Lerebours E, Savoye G, Salomez JL, Cortot A, Colombel JF, Turck D (2010) Nutritional status and growth in pediatric Crohn's disease: a population-based study. Am J Gastroenterol 105(8):1893–1900PubMedCrossRef
15.
Zurück zum Zitat Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J (2009) Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 48(2):168–174PubMedCrossRef Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J (2009) Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 48(2):168–174PubMedCrossRef
16.
Zurück zum Zitat Thangarajah D, Hyde MJ, Konteti VK, Santhakumaran S, Frost G, Fell JM (2015) Systematic review: body composition in children with inflammatory bowel disease. Aliment Pharmacol Ther 42(2):142–157PubMedCrossRef Thangarajah D, Hyde MJ, Konteti VK, Santhakumaran S, Frost G, Fell JM (2015) Systematic review: body composition in children with inflammatory bowel disease. Aliment Pharmacol Ther 42(2):142–157PubMedCrossRef
17.
Zurück zum Zitat Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM (1998) Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut. 42(2):188–194PubMedPubMedCentralCrossRef Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SM (1998) Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut. 42(2):188–194PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Sylvester FA, Leopold S, Lincoln M, Hyams JS, Griffiths AM, Lerer T (2009) A two-year longitudinal study of persistent lean tissue deficits in children with Crohn's disease. Clin Gastroenterol Hepatol 7(4):452–455PubMedCrossRef Sylvester FA, Leopold S, Lincoln M, Hyams JS, Griffiths AM, Lerer T (2009) A two-year longitudinal study of persistent lean tissue deficits in children with Crohn's disease. Clin Gastroenterol Hepatol 7(4):452–455PubMedCrossRef
19.
Zurück zum Zitat Werkstetter KJ, Ullrich J, Schatz SB, Prell C, Koletzko B, Koletzko S (2012) Lean body mass, physical activity and quality of life in paediatric patients with inflammatory bowel disease and in healthy controls. J Crohns Colitis 6(6):665–673PubMedCrossRef Werkstetter KJ, Ullrich J, Schatz SB, Prell C, Koletzko B, Koletzko S (2012) Lean body mass, physical activity and quality of life in paediatric patients with inflammatory bowel disease and in healthy controls. J Crohns Colitis 6(6):665–673PubMedCrossRef
20.
Zurück zum Zitat Burnham JM, Shults J, Semeao E, Foster B, Zemel BS, Stallings VA, Leonard MB (2004) Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res 19(12):1961–1968PubMedCrossRef Burnham JM, Shults J, Semeao E, Foster B, Zemel BS, Stallings VA, Leonard MB (2004) Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res 19(12):1961–1968PubMedCrossRef
21.
Zurück zum Zitat Wolfe RR (2006) The underappreciated role of muscle in health and disease. Am J Clin Nutr 84(3):475–482PubMedCrossRef Wolfe RR (2006) The underappreciated role of muscle in health and disease. Am J Clin Nutr 84(3):475–482PubMedCrossRef
22.
Zurück zum Zitat Gerasimidis K, McGrogan P, Edwards CA (2011) The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. J Hum Nutr Diet 24(4):313–326PubMedCrossRef Gerasimidis K, McGrogan P, Edwards CA (2011) The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. J Hum Nutr Diet 24(4):313–326PubMedCrossRef
24.
Zurück zum Zitat Ryan E, McNicholas D, Creavin B, Kelly ME, Walsh T, Beddy D (2019) Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 25(1):67–73PubMedCrossRef Ryan E, McNicholas D, Creavin B, Kelly ME, Walsh T, Beddy D (2019) Sarcopenia and inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 25(1):67–73PubMedCrossRef
25.
Zurück zum Zitat Holt DQ, Varma P, Strauss BJG, Rajadurai AS, Moore GT (2017) Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis. Eur J Clin Nutr 71(6):773–777PubMedCrossRef Holt DQ, Varma P, Strauss BJG, Rajadurai AS, Moore GT (2017) Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis. Eur J Clin Nutr 71(6):773–777PubMedCrossRef
26.
Zurück zum Zitat Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR Jr, Tudor-Locke C, Greer JL, Vezina J, Whitt-Glover MC, Leon AS (2011) 2011 compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc 43(8):1575–1581PubMedCrossRef Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR Jr, Tudor-Locke C, Greer JL, Vezina J, Whitt-Glover MC, Leon AS (2011) 2011 compendium of physical activities: a second update of codes and MET values. Med Sci Sports Exerc 43(8):1575–1581PubMedCrossRef
27.
Zurück zum Zitat Jacobs DR Jr, Ainsworth BE, Hartman TJ, Leon AS (1993) A simultaneous evaluation of 10 commonly used physical activity questionnaires. Med Sci Sports Exerc 25(1):81–91PubMedCrossRef Jacobs DR Jr, Ainsworth BE, Hartman TJ, Leon AS (1993) A simultaneous evaluation of 10 commonly used physical activity questionnaires. Med Sci Sports Exerc 25(1):81–91PubMedCrossRef
28.
Zurück zum Zitat Keats MR, Culos-Reed SN, Courneya KS, McBride M (2007) Understanding physical activity in adolescent cancer survivors: an application of the theory of planned behavior. Psychooncology. 16(5):448–457PubMedCrossRef Keats MR, Culos-Reed SN, Courneya KS, McBride M (2007) Understanding physical activity in adolescent cancer survivors: an application of the theory of planned behavior. Psychooncology. 16(5):448–457PubMedCrossRef
29.
Zurück zum Zitat Miller DJ, Freedson PS, Kline GM (1994) Comparison of activity levels using the Caltrac accelerometer and five questionnaires. Med Sci Sports Exerc 26(3):376–382PubMedCrossRef Miller DJ, Freedson PS, Kline GM (1994) Comparison of activity levels using the Caltrac accelerometer and five questionnaires. Med Sci Sports Exerc 26(3):376–382PubMedCrossRef
30.
31.
Zurück zum Zitat Crandall W, Kappelman MD, Colletti RB, Leibowitz I, Grunow JE, Ali S, Baron HI, Berman JH, Boyle B, Cohen S, del Rosario F, Denson LA, Duffy L, Integlia MJ, Kim SC, Milov D, Patel AS, Schoen BT, Walkiewicz D, Margolis P (2011) ImproveCareNow: the development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis 17(1):450–457PubMedCrossRef Crandall W, Kappelman MD, Colletti RB, Leibowitz I, Grunow JE, Ali S, Baron HI, Berman JH, Boyle B, Cohen S, del Rosario F, Denson LA, Duffy L, Integlia MJ, Kim SC, Milov D, Patel AS, Schoen BT, Walkiewicz D, Margolis P (2011) ImproveCareNow: the development of a pediatric inflammatory bowel disease improvement network. Inflamm Bowel Dis 17(1):450–457PubMedCrossRef
32.
Zurück zum Zitat Dotson JL, Crandall WV, Zhang P, Forrest CB, Bailey LC, Colletti RB, Kappelman MD (2015) Feasibility and validity of the pediatric ulcerative colitis activity index in routine clinical practice. J Pediatr Gastroenterol Nutr 60(2):200–204PubMedPubMedCentralCrossRef Dotson JL, Crandall WV, Zhang P, Forrest CB, Bailey LC, Colletti RB, Kappelman MD (2015) Feasibility and validity of the pediatric ulcerative colitis activity index in routine clinical practice. J Pediatr Gastroenterol Nutr 60(2):200–204PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT (1991) Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 12(4):439–447PubMedCrossRef Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, Griffiths AM, Katz AJ, Grand RJ, Boyle JT (1991) Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 12(4):439–447PubMedCrossRef
34.
Zurück zum Zitat Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, Kugathasan S, Pfefferkorn M, Tolia V, Evans J, Treem W, Wyllie R, Rothbaum R, del Rosario J, Katz A, Mezoff A, Oliva-Hemker M, Lerer T, Griffiths A, Pediatric Inflammatory Bowel Disease Collaborative Research Group (2005) Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 41(4):416–421PubMedCrossRef Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, Kugathasan S, Pfefferkorn M, Tolia V, Evans J, Treem W, Wyllie R, Rothbaum R, del Rosario J, Katz A, Mezoff A, Oliva-Hemker M, Lerer T, Griffiths A, Pediatric Inflammatory Bowel Disease Collaborative Research Group (2005) Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 41(4):416–421PubMedCrossRef
35.
Zurück zum Zitat Varni JW, Seid M, Rode CA (1999) The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 37(2):126–139PubMedCrossRef Varni JW, Seid M, Rode CA (1999) The PedsQL: measurement model for the pediatric quality of life inventory. Med Care 37(2):126–139PubMedCrossRef
Metadaten
Titel
Relations between disease status and body composition in pediatric inflammatory bowel disease
verfasst von
Saurabh Talathi
Pooja Nagaraj
Traci Jester
Jeanine Maclin
Taylor Knight
Margaux J. Barnes
Publikationsdatum
23.03.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Pediatrics / Ausgabe 10/2020
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-020-03629-0

Neu im Fachgebiet Pädiatrie

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Kann man Gestationsdiabetes mit oralen Antidiabetika behandeln?

Der Wunsch, Frauen mit Gestationsdiabetes eine orale Erstlinientherapie anbieten zu können, bleibt auch vorläufig ein Wunsch: Eine orale Stufentherapie hat sich in einer randomisierten Studie nicht als gleichwertig zu einer Insulintherapie erwiesen. 

Frühwarnzeichen für multiple Sklerose bei Kindern und Jugendlichen

Ein Forschungsteam aus Deutschland und Kanada hat eine Reihe metabolischer, okulärer, muskuloskelettaler, gastrointestinaler und kardiovaskulärer Symptome identifiziert, die bei Kindern und Jugendlichen der Diagnose einer multiplen Sklerose (MS) vorausgehen können.

Harnwegsinfekte: Was taugt die antibiotische Kurzzeittherapie bei Kindern?

In einer aktuellen Metaanalyse wurde untersucht, wie erfolgsversprechend eine verkürzte Antibiotikatherapie bei afebrilen Kindern mit Harnwegsinfekten im Vergleich zur Standardtherapie ist. In gewissen Fällen könnte die Kurzzeittherapie ausreichen. 

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.